论文部分内容阅读
目的探讨急性脑梗死的有效治疗措施,从而改善急性脑梗死的预后。方法129例急性脑梗死患者随机分为3组:必存(依达拉奉)组、疏血通组、疏血通与必存联合治疗组。三组在梗死分型、梗死面积、入院时神经功能缺损积分及其他治疗方面均具有可比性。分别于入院当日、第14天评定神经功能缺损,评定采用1995年全国第四届脑血管病会议制定的中国卒中量表(CSS)比较疗效。结果2周后疏血通与必存联合治疗组较单用疏血通、必存组患者的有效率明显提高(P<0.05)。结论依达拉奉与疏血通联合治疗急性脑梗死效果明显好于该两药的单药治疗,疗效显著,值得在临床推广应用。
Objective To investigate the effective treatment of acute cerebral infarction and improve the prognosis of acute cerebral infarction. Methods A total of 129 patients with acute cerebral infarction were randomly divided into 3 groups: the necessary survival (edaravone) group, Shuxuetong group, Shuxuetong and the necessary combination therapy group. The three groups were comparable in terms of infarction type, infarct size, neurological deficit at admission, and other treatments. On the 14th day of hospital admission, neurological deficit was assessed respectively, and the Chinese stroke scale (CSS), developed by the Fourth National Conference on Cerebrovascular Disease in 1995, was compared to evaluate the curative effect. Results After 2 weeks, Shuxuetong combined with the necessary treatment group than the simple Shuxuetong, must save group was significantly improved (P <0.05). Conclusion Edaravone and Shuxuetong combined treatment of acute cerebral infarction was significantly better than the two drugs monotherapy, with significant effect, it is worth in the clinical application.